Nationwide survey of implementation of 2011 Nuclear Regulatory Commission policy on release of patients after 131I therapy.
The objective of this nationwide survey was to evaluate whether there has been a change in the practice regarding hospital release of differentiated thyroid cancer patients treated with 131I since the publication of Nuclear Regulatory Commission Regulatory Issue Summary 2011-01 addressing patient release. Methods: A survey was emailed to ~25,000 members of ThyCa: Thyroid Cancer Survivors' Association, Inc. and was available online from March-August 2018. Responses were included from adult patients regarding their most recent 131I therapy received between 2011-2018 (post2011). Responses to this survey were compared to those of a similar previous survey for 131I therapies received between 1997-2009 (pre2009). Results: Of the 2,136 responses, 1,111 met the inclusion criteria. A similar percentage (~98%) of patients were given oral and/or written radiation safety instructions (RSI) post2011 and pre2009 with a shift away from nuclear medicine physicians providing instructions post2011 (43%) than pre2009 (54%; p<0.001). More patients were able to discuss and individualize the RSI post2011 (67%) than pre2009 (29%; p<0.001). However, 2% of patients do not recall ever receiving RSI post2011. Since 2011, more patients were treated as outpatients (87%) than before 2009 (66%; P<0.001). For outpatients, more patients were discharged within 30 minutes after receiving 131I therapy post2011 (78%) than pre2009 (72%; P = 0.002). The same percentage (0.6%) of patients travelled >2 hours with ≥2 occupants in the vehicle within approximately one meter of the patient post2011 and pre2009. Immediately post-therapy, a similar percentage of patients stayed in a non-private residence post2011 (4%) and pre2009 (5%; P = 0.28). Of the 27 outpatients released within 30 minutes to non-private residences, two patients received 5.55-11.1 GBq (150-299 mCi) of 131I. Conclusion: This survey suggests that since publication of the Nuclear Regulatory Commission Regulatory Issue Summary 2011-01 regarding patient release after radioiodine therapy, there has been improvements in some radiation safety practices on release of outpatients, and in patient compliance on travel and lodging.